Nuvation Bio (NYSE:NUVB – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12), FiscalAI reports. Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%. The company had revenue of $44.95 million for the quarter, compared to the consensus estimate of $34.39 million.
Here are the key takeaways from Nuvation Bio’s conference call:
- IBTROZI sales and market position strengthened: U.S. net product revenue rose 18% sequentially to $27.5 million, and the company said IBTROZI led the market in active patients and held more than 60% of first-line new patient starts.
- The overall ROS1 TKI market saw a roughly 15% decline in new patient starts during the quarter, while management noted that the pool of patients switching from older therapies is shrinking. Nuvation said future growth increasingly depends on first-line adoption, better testing, and converting patients to targeted treatment.
- Safusidenib advanced toward potential near-term data: The company cited encouraging long-term Phase II results and FDA Fast Track designation, and expects initial response data from two studies could emerge in 2027; randomized studies with progression-free survival endpoints are expected to take longer, potentially until 2029 or beyond.
- Nuvation reported $663.4 million in cash, cash equivalents, and marketable securities and said it believes it has sufficient capital to reach profitability. Management said IBTROZI’s quarterly revenue run rate now covers its launch-related expenses on a standalone basis, while operating expenses were $75.2 million for the quarter.
Nuvation Bio Stock Performance
Shares of NYSE NUVB opened at $4.68 on Thursday. Nuvation Bio has a one year low of $4.05 and a one year high of $9.75. The company has a current ratio of 8.37, a quick ratio of 8.14 and a debt-to-equity ratio of 0.96. The business has a fifty day simple moving average of $5.50 and a 200 day simple moving average of $5.39. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -10.64 and a beta of 1.73.
Insider Buying and Selling
In other news, insider Gary Hattersley sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total value of $709,000.00. Following the completion of the transaction, the insider directly owned 100,000 shares of the company’s stock, valued at approximately $709,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 30.11% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on NUVB. Cantor Fitzgerald began coverage on Nuvation Bio in a research report on Friday, August 21st. They issued an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, October 15th. Royal Bank Of Canada upped their target price on shares of Nuvation Bio from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Wall Street Zen lowered shares of Nuvation Bio from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Finally, Citigroup restated a “market outperform” rating on shares of Nuvation Bio in a report on Monday, October 19th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.22.
Read Our Latest Report on NUVB
About Nuvation Bio
Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.
Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.
Featured Stories
- Five stocks we like better than Nuvation Bio
- Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?
- How Much of Tesla’s Robotaxi Future Is Already Priced In?
- 3 AI Infrastructure Plays Beyond Chipmakers
- Keurig Dr Pepper’s Beverage Growth Raises a Tough Question About Its Coffee Split
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
